Guía Nacional para el Manejo de la Enfermedad por el Virus de la Chikungunya
manual de referencia rápida de anomalías congénitas e infecciones seleccionadas
A technical guide for sputum smear microscopy, initiated by the International Union against Tuberculosis, is designed to be an easy to use reference standard for the collection, storage and transport of sputum specimens and for the examination of sputum smears by direct microscopy. This edition incl...udes updates addressing bio-safety and quality assurance aspects of sputum smear microscopy.
more
The bill details procedures for accreditation and supervision of infertility clinics (and related organizations such as semen banks) handling spermatozoa or oocytes outside of the body, or dealing with gamete donors and surrogacy, ensuring that the legitimate rights of all concerned are protected, w...ith maximum benefit to the infertile couples/individuals within a recognized framework of ethics and good medical practice.
more
In 2015, the United Nations set important targets to reduce premature
cardiovascular disease (CVD) deaths by 33% by 2030. Africa disproportionately
bears the brunt of CVD burden and has one of the highest risks of dying
from non-communicable diseases (NCDs) worldwide. There is currently
an epide...miological transition on the continent, where NCDs is projected
to outpace communicable diseases within the current decade. Unchecked
increases in CVD risk factors have contributed to the growing burden of three
major CVDs—hypertension, cardiomyopathies, and atherosclerotic diseasesleading to devastating rates of stroke and heart failure. The highest age
standardized disability-adjusted life years (DALYs) due to hypertensive heart
disease (HHD) were recorded in Africa. The contributory causes of heart failure
are changing—whilst HHD and cardiomyopathies still dominate, ischemic
heart disease is rapidly becoming a significant contributor, whilst rheumatic
heart disease (RHD) has shown a gradual decline. In a continent where health
systems are traditionally geared toward addressing communicable diseases,
several gaps exist to adequately meet the growing demand imposed by CVDs.
Among these, high-quality research to inform interventions, underfunded
health systems with high out-of-pocket costs, limited accessibility and
affordability of essential medicines, CVD preventive services, and skill
shortages. Overall, the African continent progress toward a third reduction
in premature mortality come 2030 is lagging behind. More can be done in
the arena of effective policy implementation for risk factor reduction and
CVD prevention, increasing health financing and focusing on strengthening
primary health care services for prevention and treatment of CVDs, whilst
ensuring availability and affordability of quality medicines. Further, investing
in systematic country data collection and research outputs will improve the accuracy of the burden of disease data and inform policy adoption on
interventions. This review summarizes the current CVD burden, important
gaps in cardiovascular medicine in Africa, and further highlights priority
areas where efforts could be intensified in the next decade with potential
to improve the current rate of progress toward achieving a 33% reduction
in CVD mortality.
more
Handout presentations in PDF for illustrating lectures
Accessed May 2014
Practice paper in Brief 24
Containment strategies for Ebola rupture fundamental features of social, political and religious life. Control efforts that involve local people and appreciate their perspectives, social structures and institutions are therefore vital
The guide helps network managers and technical experts navigate the steps necessary for gathering, structuring, analyzing and reporting information needed to make strategic plans that improve sustainability and equity.
https://www.researchgate.net/publication/47460246_Mental_illness-stigma_and_discrimination_in_Zambia
El abuso y el uso indebido de los antibióticos en animales y humanos están contribuyendo al aumento de la resistencia a estos fármacos. Algunos tipos de bacterias causantes de infecciones humanas graves ya son resistentes a la mayoría o a la totalidad de los tratamientos... disponibles, y hay muy pocas alternativas prometedoras en fase de investigació
more
Standard Treatment Guideline
2006-2008 programme report
La résistance à un antimicrobien survient quand un micro-organisme (bactérie, virus, champignon ou parasite), devient résistant à un médicament antimicrobien vis-à-vis duquel il était auparavant sensible . Cette résistance aux antimicrobiens (RAM), concerne un large ...ventail d’agents infectieux, et de nombreux secteurs d’activités (santé humaine et animale, agro-industrie, élevage, environnement). Elle représente une menace croissante pour la santé publique et aucun pays n’est épargné. Il est particulièrement alarmant de constater la propagation rapide, dans le monde entier, des bactéries multirésistantes provoquant des infections courantes qui ne sont pas sensibles aux traitements antibiotiques habituellement utilisés, ainsi que des infections en particulier hospitalières, résistantes aux traitements antibiotiques de dernier recours . Le problème se pose actuellement en termes de développement durable : il dépasse largement le cadre de la santé humaine et interpelle le monde entier
AMR CONTROL – ÉDITION FRANÇAISE VOL.1
more
Asia-Pacific Disaster Report 2017
The report looks at the extent and impact of natural disasters across the region and how these intersect with poverty, inequality and the effects of violent conflict. But it also shows how scientific and other advances have increased the potential for building di...saster resilience and ensuring that even in the most extreme circumstances people can survive disaster impacts and rebuild their communities and livelihoods.
Disaster resilience is a key element of the 2030 Agenda for Sustainable Development. The Sustainable Development Goals are based on the premise of reaching absolutely everyone. When the drought is assessed, when the flood warnings are broadcast, when the tsunami siren sounds, the aim is to ‘leave no one behind’.
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).